Forest Submits Memantine NDA; 3 Studies With Cognitive Endpoint Underway
This article was originally published in Pharmaceutical Approvals Monthly
Forest has three backup memantine studies underway should FDA require data beyond the two trials in the NDA for moderate to severe Alzheimer’s disease, Forest VP-Investor Relations Charles Triano said during a July 17 earnings call.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class